Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
18.73
-0.38 (-1.97%)
Jul 9, 2026, 12:00 PM EDT - Market open
Apollomics Revenue
In the year 2025, Apollomics had annual revenue of $8.84M with 776.31% growth. Apollomics had revenue of $342.00K in the half year ending December 31, 2025, with 2.70% growth.
Revenue (ttm)
$8.84M
Revenue Growth
+776.31%
P/S Ratio
4.75
Revenue / Employee
$631,571
Employees
14
Market Cap
41.14M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.84M | 7.83M | 776.31% |
| Dec 31, 2024 | 1.01M | 545.00K | 117.46% |
| Dec 31, 2023 | 464.00K | -552.00K | -54.33% |
| Dec 31, 2022 | 1.02M | 1.01M | 50,700.00% |
| Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 22.33M |
| Veru Inc. | 16.89M |
| CervoMed | 2.09M |
| Nutriband | 1.80M |
| RenovoRx | 1.49M |
| ABVC BioPharma | 797.92K |
| INmune Bio | 50.00K |
APLM News
- 14 days ago - Apollomics Inc trading resumes - TheFly
- 14 days ago - Apollomics Inc trading halted, volatility trading pause - TheFly
- 14 days ago - Apollomics receives noncompliance notice from Nasdaq - TheFly
- 14 days ago - Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia - GlobeNewsWire
- 7 weeks ago - Apollomics Registration statement: Registration filing - Filings
- 2 months ago - Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - GlobeNewsWire
- 2 months ago - Apollomics Annual report: Q4 2025 - Filings
- 2 months ago - Apollomics Earnings release: Q4 2025 - Filings